- $109.43m
- $95.00m
- $82.51m
Annual income statement for CTW, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2023 July 31st | 2024 July 31st | 2025 July 31st | 2026 July 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 62.9 | 68.4 | 90.4 | 82.5 |
| Cost of Revenue | ||||
| Gross Profit | 46.7 | 52.2 | 68.8 | 54 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 57.4 | 61.8 | 86.7 | 89.6 |
| Operating Profit | 5.59 | 6.66 | 3.64 | -7.09 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 5.24 | 8.2 | 4.41 | -5.83 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 3.4 | 5.98 | 3.83 | -4.13 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 3.4 | 5.98 | 3.83 | -4.13 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 3.4 | 5.98 | 3.83 | -4.13 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 0.063 | 0.095 | 0.046 | -0.041 |